US Pharma MarketingBayer diagnoses how to build trust in cell and gene therapies
Bayer diagnoses how to build trust in cell and gene therapies is a pharma and life sciences industry update from FiercePharma. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Cell and gene therapy developers must build continuity of engagement to create trust in the modalities, according to a report by Bayer’s venture capital wing.
Source: FiercePharma